Neutrophil-Derived Cathelicidin Protects from Neointimal Hyperplasia
- 5 October 2011
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 3 (103) , 103ra98
Abstract
Cathelicidin-coated stents limit neointima formation.Keywords
This publication has 54 references indexed in Scilit:
- Host Defense Peptide LL-37 Selectively Reduces Proinflammatory Macrophage ResponsesThe Journal of Immunology, 2011
- Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting StentsJACC: Cardiovascular Interventions, 2010
- Phagocyte partnership during the onset and resolution of inflammationNature Reviews Immunology, 2010
- Role of polymorphonuclear neutrophils in atherosclerosis: Current state and future perspectivesAtherosclerosis, 2010
- Mechanisms underlying neutrophil-mediated monocyte recruitmentBlood, 2009
- Evidence that cathelicidin peptide LL‐37 may act as a functional ligand for CXCR2 on human neutrophilsEuropean Journal of Immunology, 2009
- CXCR2 Mediates the Recruitment of Endothelial Progenitor Cells During Allergic Airways RemodelingStem Cells, 2009
- Neutrophil secretion products pave the way for inflammatory monocytesBlood, 2008
- The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune systemJournal of Leukocyte Biology, 2006
- Preparation of LL-37-Grafted Titanium Surfaces with Bactericidal ActivityBioconjugate Chemistry, 2006